Category ADVANCED THERAPY MEDICINAL PRODUCT

PIER MARIA FORNASARI
2020-12-16

Teaching youngsters about the magnificent world of Advanced Therapies. RESTORE Consortium experiences a new formation/information tool for disseminating CAR-T Cells Therapy in Haematologic diseases.

“Thanks to this technology and to the specific fighting capabilities of these cells, extraordinary results have been obtained: The therapy is a new hope for patients who no longer responded to other treatments. The therapy seems to have a long-lasting effect after a single application Unlike many other therapies, which benefit only a small portion

Read More

No Comments InADVANCED THERAPY MEDICINAL PRODUCT
PIER MARIA FORNASARI
2020-12-14

Data Monitoring Committee of Pluristem Phase III Critical Limb Ischemia says primary endpoint has not been reached

The CLI study is unlikely to meet its primary endpoint by the time of the final analysis Substantial low number of events in the placebo group in the CLI study decreased the statistical power of the study to meet its primary endpoint PLX-PAD was well tolerated, and no safety concerns were raised Company to terminate the CLI study to focus on different therapeutic areas in its pipeline and expects three clinical readouts within the coming calendar year

Read More

No Comments InADVANCED THERAPY MEDICINAL PRODUCT
PIER MARIA FORNASARI
2020-11-17

For an Oxford University research, videogaming is positively correlated with well-being. RESTORE consortium videogame “Fragments of Life” helps to enter into CAR-T Cells breakthrough therapy in Acute Lymphoblastic Leukemia.

Conventional wisdom has it that too many cooks spoil the broth. But such judiciousness is not usually considered the basis for scientific pronouncements or international rulings on the need to limit the number of people in kitchens. But, when it comes to video games, conventional wisdom, not science, forms the basis for our thinking and

Read More

No Comments InADVANCED THERAPY MEDICINAL PRODUCT CAR-T
PIER MARIA FORNASARI
2020-10-11

RESTORE community has released new position paper on advanced therapies.

The RESTORE position paper represents the cumulative efforts of the RESTORE community, and the steering committee since the start of the RESTORE initiative in 2019. It outlines, in depth, the RESTORE view on why Europe should invest in Advanced Therapies, the roadblocks in Advanced Therapy development and implementation into patient care, and makes recommendations about

Read More

No Comments InADVANCED THERAPY MEDICINAL PRODUCT
PIER MARIA FORNASARI
2020-09-23

Toward an Optimized Process for Clinical Manufacturing of CAR-Treg Cell Therapy

Chimeric antigen receptor (CAR) technology and its application to regulatory T cells (Tregs) has garnered interest among researchers in the field of cell and gene therapy. Merging the benefits of CAR technology with Tregs offers a novel and promising therapeutic option for durable reshaping of undesired immune responses following solid organ or hematopoietic stem cell

Read More

No Comments InADVANCED THERAPY MEDICINAL PRODUCT
PIER MARIA FORNASARI
2020-09-21

Modulating endothelial adhesion and migration impacts stem cell therapies efficacy

Despite the first clinical studies reporting on a correlation betweenthe migration potential of transplanted stem cells and their therapeutic efficacy, it is unclear if effective stem cell therapies requirereliable and sufficient delivery of the cells to the desired anatomiclocations, as well as survival of the cellular graft. Moreover, the many complex processes involved in stem

Read More

No Comments InADVANCED THERAPY MEDICINAL PRODUCT
PIER MARIA FORNASARI
2020-08-17

Regenerative Medicine & Advanced Therapies Sector Thriving Despite COVID-19 following a new report by ARM

In the early days of COVID-19, the Alliance for Regenerative Medicine (ARM) was unsure how the pandemic and its accompanying economic downturn would affect the cell and gene therapy space. “It was a really specific time when the world and the markets were clearly reeling from the first appreciation for the seriousness of COVID-19,” Janet

Read More

No Comments InADVANCED THERAPY MEDICINAL PRODUCT
PIER MARIA FORNASARI
2020-07-26

Alliance for Regenerative Medicine: Pharmaceutical Strategy Could Save European ATMP Development

The Alliance for Regenerative Medicine (ARM) welcoming the opportunity to provide feedback on the roadmap to the EC pharmaceutical strategy has sent the following response. ARM is the leading international advocacy organisation dedicated to realizing the promise of advanced therapy medicinal products (ATMPs) and represents the interests of 350+ members worldwide and 70+ members across

Read More

No Comments InADVANCED THERAPY MEDICINAL PRODUCT
PIER MARIA FORNASARI
2020-01-29

EC approves Siponimod for secondary progressive multiple sclerosis

Mayzent (siponimod) has been approved by the European Commission (EC) for adults with secondary progressive multiple sclerosis (SPMS) based on the results of the EXPAND trial. The European Commission (EC) has approved Mayzent (siponimod) for the treatment of adults with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity. Approximately 80

Read More

No Comments InEMA
PIER MARIA FORNASARI
2020-01-27

The Alliance for Regenerative Medicine Outlines Recommendations on Enabling Cross-border and Regional Access to Advanced Therapy Medicinal Products (ATMPs) in Europe

Establish an ATMP coordination body at EU/EEA level Ensure authorities in regions of treatment are compensated for costs of treating patients from other regions Encourage greater alignment within Europe on product value assessment activities The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the cell and gene therapy and broader advanced therapies sector,

Read More

No Comments InADVANCED THERAPY MEDICINAL PRODUCT